Early pathophysiological alterations in experimental cardiomyopathy: The syrian cardiomyopathic hamster

Puerto Rico Health Sciences Journal

Volumn 27, Issue 4, 2008, Pages 307-314

  Escobales, Nelson ^a   Crespo, María J ^b  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b NONE

Author keywords

Coronary circulation; Endothelial dysfunction; Nitric oxide; Syrian cardiomyopathic hamsters; Vascular RAS

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL; CARDIOMYOPATHY; DISEASE MODEL; ENZYMOLOGY; HAMSTER; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CARDIOMYOPATHIES; CRICETINAE; DISEASE MODELS, ANIMAL; PEPTIDYL-DIPEPTIDASE A;

EID: 61549143741     PISSN: 07380658     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994;72:S3-S9.
2. Kannel WB. Incidence and Epidemiology of Heart Failure. Heart Fail Rev 2000;5:167-173.
3. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370-377.
4. Trupp RJ, Abraham WT, Lamba S. Future therapies for heart failure. Crit Care Nurs Clin North Am 2003;15:525-530.
5. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22(4 Suppl A):6A-13A.
6. Gertz EW. Cardiomyopathic Syrian hamster: A possible model of human disease. Prog Exp Tumor Res 1972;16:242-260.
7. Forman R, Parmley WW, Sonneblick EH. Myocardial contractility in relation to hypertrophy and failure in myopathic Syrian hamster. J Mol Cell Cardiol 1972;4:203-211.
8. Strobeck JE, Factor SM, Bhan A, Sole M, Liew CC, Fein F, Sonnenblick EH. Hereditary and acquired cardiomyopathies in experimental animals; mechanical, biochemical and structural features. Ann NY Acad Sci 1979;317:58-88.
9. Chien KR. Stress Pathways and Heart Failure 1999;98:555-558.
10. Kawada T, Nakatsuru Y, Sakamoto A, Koizumi T, Shin WS, Okai-Matsuo Y, Suzuki J, Uehara Y, Nakazawa M, Sato H, Ishikawa T, Toyo-oka T. Strain- and age-dependent loss of sarcoglycan complex in Cardiomyopathic hamster hearts and its re-expression by delta- sarcoglycan gene transfer in vivo. FEBS Lett 1999;458:405-408.
11. Kawada T, Nakazawa M, Nakauchi S, Yamazaki K, Shimamoto R, Urabe M, Nakata J, Hemmi C, Masui F, Nakajima T, Suzuki J, Monahan J, Sato H, Masaki T, Ozawa K, Toyo-Oka T. Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters. Proc Natl Acad Sci U S A 2002;99:901-906.
12. Strain JE, Grose RM, Factor SM. Results of endomyocardial biopsy in patients with spontaneous ventricular tachycardia but without apparent structural heart disease. Circulation 1983;68: 1171-1181.
13. Ikeda Y, Martone M, Gu Y, Hoshijima M, Thor A, Oh SS, Peterson KL, Ross J. Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol 2000;278:H1362-H1370.
14. Nishizawa T, Iwase M, Kanazawa H, Ichihara S, Ichihara G, Nagata K, Obata K,Kitaichi K, Yokoi T, atanabe M, Tsunematsu T, Ishikawa Y, Murohara T, Yokota M. Serial alterations of betaadrenergic signaling in dilated Cardiomyopathic hamsters: possible role of myocardial oxidative stress. Circ J 2004;68:1051-1060.
15. Rouleau JL, Chuck LHS, Hollosi G, Kidd P, Sievers RE, Wikman- Coffelt J, Parmley WW. Verapamil preserves myocardial contractility in the hereditary cardiomyopathy of the hamster. Circ Res 1982;50:405-412.
16. Sonnenblick EH, Fein F, Capasso JM, Factor SM. Microvascular spasm as a cause of cardiomyopathies and the calcium blocking- agent verapamil as potential primary therapy. Am J Cardiol 1985;55:179B-184B.
17. + -release channels during development of heart failure in cardiomyopathic hamsters Am J Physiol 1998;274:H1-H7.
18. De Mello WC, Crespo MJ. Correlation between changes in morphology, electrical properties and angiotensin converting enzyme activity in the failing heart. Eur J Pharmacol 1999;378:187-194.
19. Fukuchi T, Kobayashi A, Kaneko M, Ichiyama A, Yamazaki N. Possible involvement of free radicals and antioxidants in the early stages of the development of cardiomyopathy in BIO 14.6 Syrian hamster. Jpn Heart J 1991;32:655-666.
20. Gutiérrez JA, Clark SG, Giulumian AD, Fuchs LC. Superoxide anions contribute to impaired regulation of blood pressure by nitric oxide during the development of cardiomyopathy. J Pharmacol Exp Ther 1997;282:1643-1649.
21. Escobales N, Crespo MJ. Angiotensin II-dependent Vascular Alterations in Young Cardiomyopathic Hamsters: Role of Oxidative Stress. Vasc Pharmacol 2006;44:22-28.
22. Sakamoto A, Ono K, Abe M, Jasmin G, Eki T, Murakami Y, Masaki T, Toyo-oka T, Hanaoka F. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, deltasarcoglycan, in hamster: an animal model of disrupted dystrophin- associated glycoprotein complex. Proc Natl Acad Sci U S A 1997;94:13873-13878.
23. Cohn RD, Durbeej M, Moore SA, Coral-Vázquez R, Prouty S, Campbell KP. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J Clin Invest 2001;107:R1-R7.
24. McNally E, Allikian M, Wheeler MT, Mislow JM, Heydemann A. Cytoskeletal defects in cardiomyopathy. J Mol Cell Cardiol 2003;35:231-241.
25. L apidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex. Signaling strength and integrity for the sarcolemma. Circ Res 2004;94:1023-1031.
26. Sakamoto A. Electrical and ionic abnormalities in the heart of Cardiomyopathic hamsters: In quest of a new paradigm for cardiac failure and lethal arrhythmia. Mol Cell Biochem 2004;259: 183-187.
27. Zhu T, Zhou L, Mori S, Wang Z, McTiernan CF, Qiao C, Chen C, Wang DW, Li J, Xiao X. Sustained whole-body functional rescue n congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 2005;112:2650-2659.
28. Nigro V, de Sá Moreira E, Piluso G, Vainzof M, Belsito A, Politano L, Puca AA, Passos-Bueno MR, Zatz M. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet 1996;14:195-198.
29. Tsubata S, Bowles KR, Vatta M, Zintz C, Titus J, Muhonen L, Bowles NE, Towbin JA. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 2000;106:655-662.
30. Politano L, Nigro V, Passamano L, Petretta V, Comi LI, Papparella S, Nigro G, Rambaldi PF, Raia P, Pini A, Mora M, Giugliano MA, Esposito MG, Nigro G. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 2001;11: 178-185.
31. Moore SA, Shilling CJ, Westra S, Wall C, Wicklund MP, Stolle C, Brown CA, Michele DE, Piccolo F, Winder TL, Stence A, Barresi R, King N, King W, Florence J, Campbell KP, Fenichel GM, Stedman HH, Kissel JT, Griggs RC, Pandya S, Mathews KD, Pestronk A, Serrano C, Darvish D, Mendell JR. Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol 2006;65:995-1003.
32. Factor SM, Minase T, Cho S, Dominitz R, Sonnenblick EH. Microvascular spasm in the cardiomyopathic Syrian hamster: a preventable cause of focal myocardial necrosis. Circulation 1982;66: 342-354.
33. Kawano H, Ogawa H. Endothelial function and coronary spastic angina. Intern Med 2005;44:91-99.
34. Wheeler MT, Korcarz CE, Collins KA, Lapidos KA, Hack AA, Lyons MR, Zarnegar S, Earley JU, Lang RM, McNally EM. Second coronary artery vasospasm promotes cardiomyopathy progression. Am J Pathol 2004;1063-1071.
35. Frishman W, Sica DA. Calcium Channel Blockers. In "Cardiovascular Pharmacotherapeutics" Ed. By WH Frishman, EH Sonnenblick, and Sica DA. Vol. 1, Ch 9, 2003: p. 105-130.
36. Coral-Vázquez R, Cohn R, Moore SA, Hill JA, Weiss RM, Davisson RL, Straub V, Barresi R, Bansai D, Hrstka RF, Williamson R, Campbell KP. Disruption of sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy. Cell 1999;98:465-474.
37. Wheeler MT, Allikian MJ, Heydemann A, McNally EM. The sarcoglycan complex in striated and vascular smooth muscle. Cold Spring Harb Symp Quant Biol 2002;67:389-397.
38. Crespo MJ, Escobales N, Altieri PI. Altered Vascular Function in Early Stages of Heart Failure in Hamsters. J Card Fail 1997;3: 311-318.
39. Crespo MJ. Vasular Alterations During the Development and Progression of Experimental Heart Failure. J Card Fail 1999;5:55-63.
40. Crespo MJ, Altieri PI, Escobales N. Enhanced Contractility of Ang II in the Aorta of Cardiomyopathic Hamsters is Mediated by n Increased Ang II-Binding Capacity and Release of ET-1. Vasc Pharmacol 2006;44:247-252.
41. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A sub study of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-1729.
42. Swedberg K, Eneroth P, Kjekshus J, Wilhelmesen L, for the CONSENSUS trial study Group. Hormones regulating cardiovascular function in patients with sever congestive heart failure and their relation to mortality. Circulation 1990;82:1730-1736.
43. Hintze TH, Wang J, Seyedi N, Wolin MS. Role of EDRF/NO in chronic high coronary blood flow states during myocardial dysfunction and failure. In "Flow-dependent Regulation of Vascular Function", Edited by JA Bevan, G Kaley, and GM Rubanyi, Oxford University Press, Ch 15, 1995: p. 320-337.
44. Mollnau H, Oelze M, August M, Wendt M, Daiber A, Schulz E, Baldus S, Kleschyov AL, Materne A, Wenzel P, Hink U, Nickenig G, Fleming I, Munzel T. Mechanisms of increased vascular superoxide production in an experimental model of idiopathic dilated cardiomyopathy. Arterioscler Thromb Vasc Biol 2005;25:2554-2559.
45. Noll G, Tschudi MR, Novosel D, Luscher TF. Activity of the Larginine/ nitric oxide pathway and endothelin-1 in experimental heart failure. J Cardiovasc Pharmacol 1994;23:916-921.
46. B user PT, Camacho SA, Wu ST, Higgins CB, Jasmin G, Parmley WW, Wikman-Coffelt J. The effect of dobutamine on myocardial performance and high-energy phosphate metabolism at different stages of heart failure in Cardiomyopathic hamsters: a 31P MRS study. Am Heart J 1989;118:86-91.
47. Tanguay M, Jasmin G, Blaise G, Dumont L. Resistance of the failing dystrophic hamster heart to the cardioprotective effects of diltiazem and clentiazem: evidence of coronary vascular dysfunctions. Can J Physiol Pharmacol 1995;73:1108-1117.
48. Véronneau M, Tanguay M, Fontaine E, Jasmin G, Dumont L. Reactivity to endothelium-dependent and -independent vasoactive substances is maintained in coronary resistance vessels of the failing hamster heart. Cardiovasc Res 1997;33:623-630.
49. Brayden JE, Nelson MT. Regulation of arterial tone by activation of calcium-dependent potassium channels. Science 1992;256:532-535.
50. Cowan CL, Palacino JJ, Najibi S, Cohen RA. Potassium channelmediated relaxation to acetylcholine in rabbit arteries. J Pharmacol Exp Ther 1993;266:1482-1489.
51. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999;31:61-74.
52. + channels in mediating heterogeneous microvascular responses to acetylcholine in different vascular beds. J Pharm Exptl Ther 1997;282:1473-1479.
53. +-channel inhibition by reactive oxygen species. Am J Physiol Cell Physiol 2002;282:C461-C471.
54. + channels of porcine coronary artery smooth muscle cells. Eur J Pharmacol 2006;546:109-119.
55. Fuchs LC. Superoxide anions contribute to impaired endotheliumdependent relaxation in coronary arteries of young Cardiomyopathic hamsters. Endothelium 1996;4:141-149.
56. Drelicharz L, Kozlovski V, Skorka T, Heinze-Paluchowska S, Jasinski A, Gebska A, Guzik T, Olszanecki R, Wojnar L, Mende U, Csanyi G, Chlopicki S. NO and PGI2 in coronary endothelial dysfunction in transgenic mice with dilated cardiomyopathy. Basic Res Cardiol 2008;103:417-430.
57. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005;25:1767-1775.
58. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003;93:767-775.
59. Hermsmeyer K, Miyagawa K, Kelley ST, Rösch J, Hall AS, Axthelm MK, Greenberg B. Reactivity-based coronary vasospasm independent of atherosclerosis in rhesus monkeys. J Am Coll Cardiol 1997;29:671-680.
60. Hirsch A, Talsness C, Schunkert H, Paul M, Dzau V. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69:475-482.
61. Nakamura F, Nagano M, Kobayashi R, Higaki J, Mikami H, Kawaguchi N, Onishi S, Ogihara T. Chronic administration of angiotensin II receptor antagonist TCV-116 in cardiomyopathic hamsters. Am J Physiol 1994;267:H2297-H2304.
62. Kato Y, Iwase M, Takagi K, Nishizawa T, Kanazawa H, Matsushita A, Umeda H, Izawa H, Noda A, Koike Y, Nagata K, Yokota M Differential myolysis of myocardium and skeletal muscle in hamsters with dilated cardiomyopathy: beneficial protective effect of diltiazem. Circ J 2006;70:1497-1502.
63. Zhang C, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003;92:322-329.
64. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-1052.
65. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascula renin-angiotensin system in myointimal hyperplasia. Hypertension 1991;18(4 Suppl):II100-II105.
66. Ohishi M, Ueda M, Rakugi H, Okamura A, Naruko T, Becker AE, Hiwada K, Kamitani A, Kamide K, Higaki J, Ogihara T. Upregulation of Angiotensin- Converting Enzyme During the Healing Process After Injury at the Site of Percutaneous Transluminal Coronary Angioplasty in Humans. Circulation 1997;96:3328-3337.
67. Fukuhara M, Geary RL, Diz DI, Gallagher PE, Wilson JA, Glazier SS, Dean RH, Ferrario CM. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000;35:353-359.
68. Suda O, Tsutsui M, Morishita T, Tanimoto A, Horiuchi M, Tasaki H, Huang PL, Sasaguri Y, Yanagihara N, Nakashima Y. Long-term treatment with Nω-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endotelial nitric oxide synthase-deficient mice. Circulation 2002;106:1729-1735.
69. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, Toyohira Y, Hayashida Y, Sasaguri Y, Ueta Y, Nakashima Y, Yanagihara N. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004;24:1682-1688.
70. L andmesser U, Drexler H. Oxidative stress, the renin-angiotensin system and atherosclerosis. Eur Heart J Supplements 2003;5(Suppl A):A3-A7.
71. Kubo-Inoue M, Egashira K, Usui M, Takemoto M, Ohtani K, Katoh M, Shimokawa H, Takeshita A. Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery. Am J Physiol Heart Circ Physiol 2002;282: H1478-H1484.
72. L ee J, Kim S, Oh Y, Ryu SY, Kim SW. Upregulation of vascular renin-angiotensin and endothelin systems in rats inhibited of nitric oxide synthesis. Pharmacol Res 2002;46:383-387.
73. Takemoto M, Egashira K,Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997;99:278-287.
74. Hasegawa K, Wakino S, Tatematsu S, Yoshioka K, Homma K, Sugano N, Kimoto M, Hayashi K, Itoh H. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginine dimethylaminohydrolase 2. Circ Res 2007;101:e2-e10.
75. Wang H, Wang Z, Chen J, Wu J. Apoptosis induced by NO via phosphorylation of p38 MAPK that stimulates NF-kappaB, p53 and caspase-3 activation in rabbit articular chondrocytes. Cell Biol Int 2007;31:1027-1035.
76. Moniwa N, Agatha J, Hagiwara M, Ura N, Shimamoto K. The role of bradykinin B1 receptor on cardiac remodeling in strokeprone spontaneously hypertensive rats (SHR-SP). Biol Chem 2006;387:203-209.
77. Escobales N, Crespo MJ. Oxidative-nitrosative Stress in Hypertension. Curr Vasc Pharmacol 2005;3:231-246.
78. Kyoi S, Otani H, Matsuhisa S, Akita Y, Tatsumi K, Enoki C, Fujiwara H, Imamura H, Kamihata H, Iwasaka T Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster. Cardiovasc Res 2006;69:888-898.
79. Camisi PG, Crea, F. Coronary Microvascular Dysfunction. N Engl J Med 2007;356:830-840.
80. Crespo MJ, Cruz N, Altieri PI, Escobales N. Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster. J Cardiovasc Pharmacol Ther 2008;13:199-206.